Details for Patent: 11,795,176

Which drugs does patent 11,795,176 protect, and when does it expire?

Patent 11,795,176 protects ZUNVEYL and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 11,795,176

Title:	Solid forms of Alpha-1062 gluconate
Abstract:	The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for manufacturing crystalline forms and compositions comprising said crystalline forms.
Inventor(s):	Fred D. Sancilio
Assignee:	Alpha Cognition Inc
Application Number:	US17/575,025
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,795,176
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,795,176

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes				Y		TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No				Y		TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No				Y		TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE

International Family Members for US Patent 11,795,176

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022208641
Canada	3205859
China	116761612
European Patent Office	4029867